Abstract
Purpose
Improved early diagnosis and determination of aggressiveness of prostate cancer (PC) is important to select suitable treatment options and to decrease over‐treatment. The conventional marker is total prostate specific antigen (PSA) levels in blood, but lacks specificity and ability to accurately discriminate indolent from aggressive disease.
Experimental design
In this study, we sought to identify a serum biomarker signature associated with metastatic PC. We measured 157 analytes in 363 serum samples from healthy subjects, patients with non‐metastatic PC and patients with metastatic PC, using a recombinant antibody microarray.
Results
A signature consisting of 69 proteins differentiating metastatic PC patients from healthy controls was identified.
Conclusions and clinical relevance
The clinical value of this biomarker signature requires validation in larger independent patient cohorts before providing a new prospect for detection of metastatic PC.
Improved early diagnosis and determination of aggressiveness of prostate cancer (PC) is important to select suitable treatment options and to decrease over‐treatment. The conventional marker is total prostate specific antigen (PSA) levels in blood, but lacks specificity and ability to accurately discriminate indolent from aggressive disease.
Experimental design
In this study, we sought to identify a serum biomarker signature associated with metastatic PC. We measured 157 analytes in 363 serum samples from healthy subjects, patients with non‐metastatic PC and patients with metastatic PC, using a recombinant antibody microarray.
Results
A signature consisting of 69 proteins differentiating metastatic PC patients from healthy controls was identified.
Conclusions and clinical relevance
The clinical value of this biomarker signature requires validation in larger independent patient cohorts before providing a new prospect for detection of metastatic PC.
| Original language | English |
|---|---|
| Article number | 2000025 |
| Number of pages | 13 |
| Journal | Proteomics - Clinical applications |
| Volume | 15 |
| Issue number | 2-3 |
| Early online date | 13 Feb 2021 |
| DOIs | |
| Publication status | Published - 4 May 2021 |
Bibliographical note
Funding Information:This study was supported by funding from Vinnova (UDI 2016‐00462) and CREATE Health Cancer Center at Lund University. Hans Lilja was supported in part by the National Institutes of Health/National Cancer Institute (NIH/NCI) with a Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center (MSKCC) [P30 CA008748], a SPORE grant in Prostate Cancer [P50‐CA92629], the Sidney Kimmel Center for Prostate and Urologic Cancers, David H. Koch through the Prostate Cancer Foundation, the Swedish Cancer Society (CAN 2017/559), and the Swedish Research Council (VR‐MH project no. 2016–02974). The ProtecT trial is funded by the UK National Institute for Health Research Health Technology Assessment Program (projects 96/20/06, 96/20/99, http://www.nets.nihr.ac.uk/projects/hta/962099 ) with the University of Oxford as sponsor. Department of Health disclaimer: The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Department of Health. Freddie Hamdy is supported in part by the National Institute for Health Research Oxford Biomedical Research Centre (Oxford NIHR BRC).
Publisher Copyright:
© 2021 The Authors. Proteomics – Clinical Applications published by Wiley-VCH GmbH
Keywords
- affinity proteomics
- antibody microarrays
- biomarkers
- cancer
- prostate cancer
Access to Document
- Full-text PDF (final published version)
This is the final published version of the article (version of record). It first appeared online via Wiley at https://onlinelibrary.wiley.com/doi/10.1002/prca.202000025 . Please refer to any applicable terms of use of the publisher.
Handle.net
Full-text PDF (author’s accepted manuscript)
Accepted author manuscript, 412 KB